Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1348062

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1348062

Blood Group Typing Market by Product, Test Type, Technique, End User, Region - Global Forecast to 2028

PUBLISHED:
PAGES: 214 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

The blood group typing market is valued at an estimated USD 2.0 billion in 2023 and is projected to reach USD 3.0 billion by 2028, at a CAGR of 8.7% during the forecast period. Severe post-partum hemorrhage (bleeding during delivery or after childbirth) is the leading cause of maternal mortality worldwide. Additionally, childhood anemia, trauma, and congenital blood disorders are other emergency conditions requiring blood transfusions. Urgent and timely treatment is required to manage these patients, including transfusion of blood and blood products. The overall increase in the number of blood transfusions is leading to the increased adoption of blood group typing methods in order to ensure the safety and compatibility of the transfused blood. This is driving the overall growth of the market.

"Antibody screening segment accounted for the highest growth rate in the blood group typing market, by test type, during the forecast period."

The blood group typing market is bifurcated into ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing on the basis of test type. The antibody screening segment in the blood group typing market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as autoimmune disorders and cancers. The use of antibody screening methods is also growing due to the rising focus on R&D in antigen-specific therapies in response to the increasing incidence of chronic diseases.

"PCR-based and microarray techniques segment accounted for the highest growth rate in the blood group typing market, by techniques, during the forecast period."

The global blood group typing market is bifurcated into assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques. The PCR-based and microarray techniques segment is currently witnessing the highest growth rate within the blood group typing market. PCR-based techniques have emerged as powerful tools to accurately identify and characterize rare blood group antigens at the genetic level. However, PCR methods have limited throughput and multiplex capacity. To overcome these limitations, microarray platforms have been developed. Microarray platforms give more detailed information about blood group antigens than basic PCR methods. Owing to the advantages of these methods, such as high accuracy over traditional methods, their adoption is increasing among end users.

"Asia Pacific: The fastest-growing region blood group typing market"

The global blood group typing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as government efforts to increase awareness about the importance of blood donations and regular health check-ups, continuously rising healthcare expenditures, an increasing number of hospitals in India and China, and strengthening research bases for diagnostic procedures across India, China, and Japan. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.

The break-up of the profile of primary participants in the blood group typing market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), Immucor, Inc. (US), Danaher (US), Merck KGaA (Germany), Quotient Limited (Switzerland), Novacyt (France), BAG Health Care GmbH (Germany), Rapid Labs Ltd (UK), Agena Bioscience, Inc. (US), Biorex Diagnostics (UK), HUMAN Gesellschaft fur Biochemica und Diagnostica mbH (Germany), Prestige Diagnostics (UK), Span Diagnostics SARL (France), DIALAB GmbH (Austria), Lorne Laboratories Limited (UK), Atlas Medical GmbH (Germany), Torax Biosciences Limited (Northern Ireland), Fortress Diagnostics (UK), AXO Science (France), Maxwin Health Care Pvt. Ltd. (India), Anamol Laboratories Pvt. Ltd. (India), J. Mitra & Co. Pvt. Ltd. (India), and MedSource Ozone Biomedicals Pvt. Ltd. (India).

Research Coverage:

This research report categorizes the blood group typing market by product & service (consumables, instruments, and services & software), test type (ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing), technique (assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques), end user (hospitals, blood banks, clinical laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, and opportunities, influencing the growth of the blood group typing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the blood group typing market. Competitive analysis of upcoming startups in the blood group typing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall blood group typing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations, growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions, increasing demand for blood group typing in prenatal testing, high usage of blood group typing in forensic sciences, extensive R&D in blood typing, and stringent regulatory standards for blood transfusion), restraints (emergence of blood alternatives), and opportunities (growth opportunities in emerging economies) influencing the growth of the blood group typing market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the blood group typing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the blood group typing market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the blood group typing market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), and Immucor, Inc. (US), among others in the blood group typing market strategies.
Show more
Product Code: MD 5210

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 BLOOD GROUP TYPING MARKET
    • 1.3.2 GEOGRAPHIC SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 BLOOD GROUP TYPING MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 BLOOD GROUP TYPING MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RISK ASSESSMENT
    • 2.8.1 RISK ASSESSMENT: BLOOD GROUP TYPING MARKET
  • 2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

    • FIGURE 8 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 BLOOD GROUP TYPING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 BLOOD GROUP TYPING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 BLOOD GROUP TYPING MARKET OVERVIEW
    • FIGURE 13 INCREASING PREVALENCE OF CHRONIC CONDITIONS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
  • 4.2 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
    • FIGURE 14 CONSUMABLES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
  • 4.3 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2023 VS. 2028
    • FIGURE 15 ABO BLOOD TESTS & RH TYPING SEGMENT TO DOMINATE MARKET IN 2028
  • 4.4 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2023 VS. 2028
    • FIGURE 16 ASSAY-BASED TECHNIQUES SEGMENT TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD
  • 4.5 BLOOD GROUP TYPING MARKET, BY END USER, 2023 VS. 2028
    • FIGURE 17 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
  • 4.6 BLOOD GROUP TYPING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN BLOOD GROUP TYPING MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 BLOOD GROUP TYPING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations
    • FIGURE 20 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 2015-2030 (MILLION INDIVIDUALS)
      • 5.2.1.2 Growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions
      • 5.2.1.3 Increasing demand for blood group typing in prenatal testing
      • 5.2.1.4 High usage of blood group typing in forensic sciences
      • 5.2.1.5 Extensive R&D in blood typing
      • 5.2.1.6 Stringent regulatory standards for blood transfusion
    • TABLE 1 LIST OF PRODUCTS CBER REGULATES
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Emergence of blood alternatives
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging economies
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
    • TABLE 2 INDICATIVE PRICING FOR BLOOD GROUP TYPING PRODUCTS
    • 5.3.2 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS, BY KEY PLAYER
    • TABLE 3 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS
  • 5.4 PATENT ANALYSIS
    • FIGURE 21 PATENT ANALYSIS FOR BLOOD GROUP TYPING REAGENTS (JANUARY 2013-DECEMBER 2022)
    • 5.4.1 LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS OF BLOOD GROUP TYPING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 23 BLOOD GROUP TYPING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 24 BLOOD GROUP TYPING MARKET: ECOSYSTEM ANALYSIS
    • 5.7.1 BLOOD GROUP TYPING MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 BLOOD GROUP TYPING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    • TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
      • 5.9.1.2 Canada
    • 5.9.2 EUROPE
    • TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 China
      • 5.9.3.2 Japan
    • TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.3.3 India
    • 5.9.4 LATIN AMERICA
      • 5.9.4.1 Brazil
    • 5.9.5 MIDDLE EAST
  • 5.10 TRADE ANALYSIS
    • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 KEY CONFERENCES & EVENTS IN 2023-2024
    • TABLE 13 BLOOD GROUP TYPING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.13 PESTLE ANALYSIS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 25 REVENUE SHIFT IN BLOOD GROUP TYPING MARKET
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS
    • TABLE 14 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS (%)
    • 5.15.2 BUYING CRITERIA
    • FIGURE 27 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
    • TABLE 15 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
    • 5.15.3 CASE STUDY ANALYSIS

6 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 16 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 6.2 CONSUMABLES
    • TABLE 17 KEY CONSUMABLES AVAILABLE IN MARKET
    • TABLE 18 BLOOD GROUP TYPING CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 19 BLOOD GROUP TYPING CONSUMABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 6.2.1 ANTISERA REAGENTS
      • 6.2.1.1 Increasing demand for cost-effective blood typing solutions to support uptake of antisera reagents
    • TABLE 20 ANTISERA REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.2 ANTI-HUMAN GLOBULIN REAGENTS
      • 6.2.2.1 Increasing number of organ transplantations to drive uptake of AHG reagents
    • TABLE 21 ANTI-HUMAN GLOBULIN REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.3 RED BLOOD CELL REAGENTS
      • 6.2.3.1 Higher compatibility of red blood cell reagents with variety of blood group typing techniques to support uptake
    • TABLE 22 RED BLOOD CELL REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.4 BLOOD BANK SALINE
      • 6.2.4.1 Ability of blood bank saline to preserve integrity of RBCs to support market growth
    • TABLE 23 BLOOD BANK SALINE MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 GROWING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST DEMAND FOR BLOOD GROUP TYPING INSTRUMENTS
    • TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
    • TABLE 25 BLOOD GROUP TYPING INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 SERVICES & SOFTWARE
    • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN MARKET SEGMENT
    • TABLE 26 BLOOD GROUP TYPING SERVICES & SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)

7 BLOOD GROUP TYPING MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
    • TABLE 27 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
  • 7.2 ABO BLOOD TESTS & RH TYPING
    • 7.2.1 GROWING AWARENESS OF IMPORTANCE OF BLOOD DONATION TO DRIVE GROWTH
    • TABLE 28 BLOOD GROUP TYPING MARKET FOR ABO BLOOD TESTS & RH TYPING, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 ANTIBODY SCREENING
    • 7.3.1 INCREASING INCIDENCE OF CANCER AND AUTOIMMUNE DISORDERS TO SUPPORT GROWTH
    • TABLE 29 BLOOD GROUP TYPING MARKET FOR ANTIBODY SCREENING, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 HLA TYPING
    • 7.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO STIMULATE DEMAND FOR HLA TYPING
    • TABLE 30 BLOOD GROUP TYPING MARKET FOR HLA TYPING, BY REGION, 2021-2028 (USD MILLION)
  • 7.5 CROSS-MATCHING TESTS
    • 7.5.1 GROWING NEED FOR BLOOD TRANSFUSION TO PROPEL MARKET GROWTH
    • TABLE 31 BLOOD GROUP TYPING MARKET FOR CROSS-MATCHING TESTS, BY REGION, 2021-2028 (USD MILLION)
  • 7.6 ANTIGEN TYPING
    • 7.6.1 INCREASING CASES OF INCORRECT BLOOD TRANSFUSION TO FUEL GROWTH
    • TABLE 32 BLOOD GROUP TYPING MARKET FOR ANTIGEN TYPING, BY REGION, 2021-2028 (USD MILLION)

8 BLOOD GROUP TYPING MARKET, BY TECHNIQUE

  • 8.1 INTRODUCTION
    • TABLE 33 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
  • 8.2 ASSAY-BASED TECHNIQUES
    • 8.2.1 AUTOMATION, SENSITIVITY, OBJECTIVITY, AND ADAPTABILITY OF ASSAY-BASED TECHNIQUES TO BOOST ADOPTION
    • TABLE 34 BLOOD GROUP TYPING MARKET FOR ASSAY-BASED TECHNIQUES, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 PCR-BASED AND MICROARRAY TECHNIQUES
    • 8.3.1 HIGH ACCURACY OF PCR-BASED AND MICROARRAY TECHNIQUES TO SUPPORT GROWTH
    • TABLE 35 BLOOD GROUP TYPING MARKET FOR PCR-BASED AND MICROARRAY TECHNIQUES, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 MASSIVELY PARALLEL SEQUENCING
    • 8.4.1 ABILITY TO DETECT LOW-FREQUENCY ALLELES TO DRIVE DEMAND FOR MPS TECHNIQUES
    • TABLE 36 BLOOD GROUP TYPING MARKET FOR MASSIVELY PARALLEL SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 OTHER TECHNIQUES
    • TABLE 37 BLOOD GROUP TYPING MARKET FOR OTHER TECHNIQUES, BY REGION, 2021-2028 (USD MILLION)

9 BLOOD GROUP TYPING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 38 BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 PRIMARY NOTES
    • 9.2.1 KEY PRIMARY INSIGHTS
  • 9.3 HOSPITALS
    • 9.3.1 INCREASING NUMBER OF HOSPITALS TO BOOST GROWTH
    • TABLE 39 BLOOD GROUP TYPING MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 BLOOD BANKS
    • 9.4.1 GROWING NUMBER OF BLOOD DONATIONS TO PROPEL MARKET GROWTH
    • TABLE 40 BLOOD GROUP TYPING MARKET FOR BLOOD BANKS, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 CLINICAL LABORATORIES
    • 9.5.1 GROWING PREVALENCE OF BLOOD DISORDERS TO BOLSTER GROWTH
    • TABLE 41 BLOOD GROUP TYPING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.6 OTHER END USERS
    • TABLE 42 BLOOD GROUP TYPING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

10 BLOOD GROUP TYPING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 43 BLOOD GROUP TYPING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: BLOOD GROUP TYPING MARKET SNAPSHOT
    • TABLE 44 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 48 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 Increasing prevalence of chronic conditions to drive market growth
    • TABLE 49 ESTIMATED NUMBER OF SINGLE ORGAN TRANSPLANTS PERFORMED IN US
    • TABLE 50 US: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 51 US: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 52 US: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 53 US: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing incidence of blood cancer to boost market
    • TABLE 54 CANADA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 55 CANADA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 56 CANADA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 57 CANADA: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 58 EUROPE: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 60 EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 61 EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Increasing healthcare expenditure to drive market growth
    • TABLE 63 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 64 GERMANY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 65 GERMANY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 GERMANY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 67 GERMANY: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Growing number of road accidents to propel market growth
    • TABLE 68 UK: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 69 UK: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 70 UK: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 71 UK: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Rising R&D expenditure in France to drive market growth
    • TABLE 72 FRANCE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 73 FRANCE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 FRANCE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 75 FRANCE: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing number of blood donors to favor market growth
    • TABLE 76 ITALY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 77 ITALY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 ITALY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 79 ITALY: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Consolidation of laboratories in Spain to support market growth
    • TABLE 80 SPAIN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 81 SPAIN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 82 SPAIN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 83 SPAIN: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 84 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
    • TABLE 85 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 86 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 88 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 29 ASIA PACIFIC: BLOOD GROUP TYPING MARKET SNAPSHOT
    • TABLE 89 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 10.4.2 CHINA
      • 10.4.2.1 Growing public access to modern healthcare to drive market growth
    • TABLE 94 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 95 CHINA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 96 CHINA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 CHINA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 98 CHINA: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
    • TABLE 99 JAPAN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 100 JAPAN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 JAPAN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 102 JAPAN: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing private & public investments in healthcare system to drive market growth
    • TABLE 103 INDIA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 104 INDIA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 INDIA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 106 INDIA: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 107 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 108 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 109 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 110 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE TO SUPPORT MARKET GROWTH
    • TABLE 111 BRAZIL: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 112 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 113 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 115 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.2 LATIN AMERICA: RECESSION IMPACT
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • TABLE 116 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 117 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • TABLE 118 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 119 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES OF KEY PLAYERS
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GROUP TYPING MARKET
    • TABLE 120 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD GROUP TYPING MANUFACTURING COMPANIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 31 BLOOD GROUP TYPING MARKET SHARE, BY KEY PLAYER (2022)
    • TABLE 121 BLOOD GROUP TYPING MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022)
    • 11.5.1 LIST OF EVALUATED VENDORS
    • 11.5.2 STARS
    • 11.5.3 EMERGING LEADERS
    • 11.5.4 PERVASIVE PLAYERS
    • 11.5.5 PARTICIPANTS
    • FIGURE 32 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT, 2022
  • 11.6 COMPETITIVE EVALUATION QUADRANT FOR START-UPS/SMES (2022)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 33 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
    • 11.6.5 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
    • FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET
    • TABLE 122 BLOOD GROUP TYPING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 123 COMPANY PRODUCT & SERVICE FOOTPRINT
    • TABLE 124 COMPANY REGIONAL FOOTPRINT
    • TABLE 125 BLOOD GROUP TYPING MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 11.7 COMPETITIVE SCENARIO
    • 11.7.1 PRODUCT LAUNCHES
    • TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-AUGUST 2023)
    • 11.7.2 DEALS
    • TABLE 127 KEY DEALS (JANUARY 2020-AUGUST 2023)

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 12.1 KEY PLAYERS
    • 12.1.1 BIO-RAD LABORATORIES, INC.
    • TABLE 128 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.2 QUIDELORTHO CORPORATION
    • TABLE 129 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
    • FIGURE 36 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.3 GRIFOLS, S.A.
    • TABLE 130 GRIFOLS, S.A.: BUSINESS OVERVIEW
    • FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022)
    • 12.1.4 THERMO FISHER SCIENTIFIC INC.
    • TABLE 131 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 12.1.5 IMMUCOR, INC.
    • TABLE 132 IMMUCOR, INC.: BUSINESS OVERVIEW
    • 12.1.6 QUOTIENT LIMITED
    • TABLE 133 QUOTIENT LIMITED: BUSINESS OVERVIEW
    • FIGURE 39 QUOTIENT LIMITED: COMPANY SNAPSHOT (2021)
    • 12.1.7 DANAHER
    • TABLE 134 DANAHER: BUSINESS OVERVIEW
    • FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022)
    • 12.1.8 MERCK KGAA
    • TABLE 135 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 12.1.9 NOVACYT
    • TABLE 136 NOVACYT: BUSINESS OVERVIEW
    • FIGURE 42 NOVACYT: COMPANY SNAPSHOT (2022)
    • 12.1.10 BAG HEALTH CARE GMBH
    • TABLE 137 BAG HEALTH CARE GMBH: BUSINESS OVERVIEW
    • 12.1.11 RAPID LABS LTD.
    • TABLE 138 RAPID LABS LTD.: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 AGENA BIOSCIENCE, INC.
    • TABLE 139 AGENA BIOSCIENCE, INC.: COMPANY OVERVIEW
    • 12.2.2 BIOREX DIAGNOSTICS
    • TABLE 140 BIOREX DIAGNOSTICS: COMPANY OVERVIEW
    • 12.2.3 HUMAN GESELLSCHAFT FUR BIOCHEMICA UND DIAGNOSTICA MBH
    • TABLE 141 HUMAN GESELLSCHAFT FUR BIOCHEMICA UND DIAGNOSTICA MBH: COMPANY OVERVIEW
    • 12.2.4 PRESTIGE DIAGNOSTICS
    • TABLE 142 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW
    • 12.2.5 DIALAB GMBH
    • TABLE 143 DIALAB GMBH: COMPANY OVERVIEW
    • 12.2.6 LORNE LABORATORIES LIMITED
    • TABLE 144 LORNE LABORATORIES LIMITED: COMPANY OVERVIEW
    • 12.2.7 ATLAS MEDICAL GMBH
    • TABLE 145 ATLAS MEDICAL GMBH: COMPANY OVERVIEW
    • 12.2.8 TORAX BIOSCIENCES LIMITED
    • TABLE 146 TORAX BIOSCIENCES LIMITED: COMPANY OVERVIEW
    • 12.2.9 FORTRESS DIAGNOSTICS
    • TABLE 147 FORTRESS DIAGNOSTICS: COMPANY OVERVIEW
    • 12.2.10 AXO SCIENCE
    • TABLE 148 AXO SCIENCE: COMPANY OVERVIEW
    • 12.2.11 MAXWIN HEALTH CARE PVT. LTD.
    • TABLE 149 MAXWIN HEALTH CARE PVT. LTD.: COMPANY OVERVIEW
    • 12.2.12 ANAMOL LABORATORIES PVT. LTD.
    • TABLE 150 ANAMOL LABORATORIES PVT. LTD.: COMPANY OVERVIEW
    • 12.2.13 J. MITRA & CO. PVT. LTD.
    • TABLE 151 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
    • 12.2.14 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
    • TABLE 152 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!